Patients’ Preferences Regarding Invasive Mediastinal Nodal Staging of Resectable Lung Cancer

References

• Integraal Kanker Centrum Nederland, (IKNL). Cijfers over kanker (Dutch cancer registry); 2019. Available from: http://www.cijfersoverkanker.nl/selecties/Dataset_2/img5a4b6b6782289. Accessed October 30, 2019.
   Google Scholar
• Heineman DJ, Hoeijmakers F, Beck N, et al. Impact of health care organization on surgical lung cancer care. Lung Cancer. 2019;135:181–187. doi:10.1016/j.lungcan.2019.07.028
   Web of Science ®Google Scholar
• Vilmann P, Clementsen PF, Colella S, et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Endoscopy. 2015;47(6):546–560.
   Web of Science ®Google Scholar
• Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(4):iv1–iv21. doi:10.1093/annonc/mdx222
   Web of Science ®Google Scholar
• Annema JT, van Meerbeeck JP, Rintoul RC, et al. Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA. 2010;304(20):2245–2252. doi:10.1001/jama.2010.1705
   PubMed Web of Science ®Google Scholar
• Rusch VW. Mediastinoscopy: an obsolete procedure? J Thorac Cardiovasc Surg. 2011;142(6):1400–1402. doi:10.1016/j.jtcvs.2011.10.017
   Google Scholar
• Annema JT, de Leyn P, Clementsen P, Siemsen M, Vilmann P. Mediastinoscopy after negative endoscopic mediastinal nodal staging: can it be omitted? Eur Respir J. 2015;46(6):1848–1849. doi:10.1183/13993003.01472-2015
   Web of Science ®Google Scholar
• Kim H. Reply to “are we at the dusk of mediastinoscopy in modern clinical practice?”: an irresistible trend. J Thorac Oncol. 2015;10(9):e91–e92. doi:10.1097/JTO.0000000000000595
   Web of Science ®Google Scholar
• Verhagen AFTM, Schuurbiers OCJ, Looijen-Salamon MG, et al. Mediastinal staging in daily practice: endosonography, followed by cervical mediastinoscopy. Do we really need both? Interact Cardiovasc Thorac Surg. 2013;17(5):823–828.
   Web of Science ®Google Scholar
• Bousema JE, van Dorp M, Noyez VJJM, Dijkgraaf MGW, Annema JT, van den Broek FJC. Unforeseen N2 disease after negative endosonography findings with or without confirmatory mediastinoscopy in resectable non–small cell lung cancer: a systematic review and meta-analysis. J Thorac Oncol. 2019;14(6):979–992. doi:10.1016/j.jtho.2019.02.032
   Web of Science ®Google Scholar
• Bousema JE, Dijkgraaf MGW, Papen-Botterhuis NE, et al. MEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy (MEDIASTrial): study protocol of a multicenter randomised controlled trial. BMC Surg. 2018;18(1):27. doi:10.1186/s12893-018-0359-6
   Web of Science ®Google Scholar
• Sawtooth Software. ACA technical paper V6.0; 2007.
   Google Scholar
• Gigerenzer G. The psychology of good judgment: frequency formats and simple algorithms. Med Decis Making. 1996;16(3):273. doi:10.1177/0272989X9601600312
   Web of Science ®Google Scholar
• Kuijvenhoven JC, Korevaar DA, Tournoy KG, et al. Five-year survival after endosonography vs mediastinoscopy for mediastinal nodal staging of lung cancer. JAMA. 2016;316(10):1110–1112. doi:10.1001/jama.2016.10349
   Web of Science ®Google Scholar
• Orme B. Hierarchical Bayes: Why All the Attention? Sawtooth Software Inc.; 2000.
   Google Scholar
• Turner SR, Seyednejad N, Nasir BS. Patterns of practice in mediastinal lymph node staging for non-small cell lung cancer in Canada. Ann Thorac Surg. 2018;106(2):428–434. doi:10.1016/j.athoracsur.2018.02.054
   Web of Science ®Google Scholar
• Thornblade LW, Wood DE, Mulligan MS, et al. Variability in invasive mediastinal staging for lung cancer: a multicenter regional study. J Thorac Cardiovasc Surg. 2018;155(6):2658–2671.e1. doi:10.1016/j.jtcvs.2017.12.138
   Web of Science ®Google Scholar
• Bousema JE, van Dorp M, Hoeijmakers F, et al. Guideline adherence of mediastinal staging of non-small cell lung cancer: a multicentre retrospective analysis. Lung Cancer. 2019;134:52–58. doi:10.1016/j.lungcan.2019.05.031
   PubMed Web of Science ®Google Scholar
• Schmidt K, Damm K, Prenzler A, Golpon H, Welte T. Preferences of lung cancer patients for treatment and decision-making: a systematic literature review. Eur J Cancer Care (Engl). 2016;25(4):580–591. doi:10.1111/ecc.12425
   PubMed Web of Science ®Google Scholar
• Sun H, Wang H, Xu N, et al. Patient preferences for chemotherapy in the treatment of non-small cell lung cancer: a multicenter Discrete Choice Experiment (DCE) Study in China. Patient Prefer Adherence. 2019;13:1701–1709. doi:10.2147/PPA.S224529
   PubMed Web of Science ®Google Scholar
• Mühlbacher AC, Bethge S. Patients’ preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer. Eur J Health Econ. 2015;16(6):657–670. doi:10.1007/s10198-014-0622-4
   PubMed Web of Science ®Google Scholar
• Sullivan DR, Eden KB, Dieckmann NF, et al. Understanding patients’ values and preferences regarding early stage lung cancer treatment decision making. Lung Cancer. 2019;131:47–57. doi:10.1016/j.lungcan.2019.03.009
   Web of Science ®Google Scholar
• Janssen EM, Dy SM, Meara AS, Kneuertz PJ, Presley CJ, Bridges JF. Analysis of patient preferences in lung cancer – estimating acceptable tradeoffs between treatment benefit and side effects. Patient Prefer Adherence. 2020;14:927–937. doi:10.2147/PPA.S235430
   PubMed Web of Science ®Google Scholar
• Mokhles S, Nuyttens JJME, de Mol M, et al. Treatment selection of early stage non-small cell lung cancer: the role of the patient in clinical decision making. BMC Cancer. 2018;18(1):79. doi:10.1186/s12885-018-3986-5
   PubMed Web of Science ®Google Scholar
• Abbett SK, Urman RD, Bader AM. Shared decision-making – creating pathways and models of care. Best practice & research. Clin Anaesthesiol. 2020;34(2):297–301.
   Google Scholar
• Weeks JC, Catalano PJ, Cronin A, et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367(17):1616–1625. doi:10.1056/NEJMoa1204410
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377(20):1919–1929. doi:10.1056/NEJMoa1709937
   PubMed Web of Science ®Google Scholar
• Dickhoff C, Dahele M, de Langen AJ, et al. Population-based patterns of surgical care for stage IIIA NSCLC in the Netherlands between 2010 and 2013. J Thorac Oncol. 2016;11(4):566–572. doi:10.1016/j.jtho.2016.01.002
   PubMed Web of Science ®Google Scholar
• Thomas D, Thomas D, Arnold B, et al. The significance of upfront knowledge of N2 disease in non-small cell lung cancer. World J Surg. 2018;42(1):161–171. doi:10.1007/s00268-017-4165-6
   Web of Science ®Google Scholar
• Eberhardt WEE, De Ruysscher D, Weder W, et al. 2nd ESMO consensus conference in lung cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015;26(8):1573–1588. doi:10.1093/annonc/mdv187
   PubMed Web of Science ®Google Scholar
• Hoeijmakers F, Heineman DJ, Beck N, et al. Mediastinoscopy for staging of non-small cell lung cancer: surgical performance in the Netherlands. Ann Thorac Surg. 2019;107(4):1024–1031.
   Web of Science ®Google Scholar
• Stiggelbout AM, de Haes JCJM. Patient preference for cancer therapy: an overview of measurement approaches. J Clin Oncol. 2001;19(1):220–230. doi:10.1200/JCO.2001.19.1.220
   PubMed Web of Science ®Google Scholar